Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

While progesterone receptor (PR)-targeted therapies are modestly active in patients with uterine cancer, their underlying molecular mechanisms are not well understood. The clinical use of such therapies is limited because of the lack of biomarkers that predict response to PR-agonists (progestins) or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Huang, Yan, Hu, Wei, Huang, Jie, Shen, Fangrong, Sun, Yunjie, Ivan, Cristina, Pradeep, Sunila, Dood, Robert, Haemmerle, Monika, Jiang, Dahai, Mangala, Lingegowda S., Noh, Kyunghee, Hansen, Jean M, Dalton, Heather J., Previs, Rebecca A., Nagaraja, Archana S., McGuire, Michael, Jennings, Nicholas B., Broaddus, Russell, Coleman, Robert L., Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805630/
https://ncbi.nlm.nih.gov/pubmed/29237804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados